Tags

Type your tag names separated by a space and hit enter

Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.
Surgery. 2006 Sep; 140(3):448-53.S

Abstract

BACKGROUND

Intraductal papillary-mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas have similar clinicopathologic findings. This study was intended to clarify clinicopathologic characteristics in IPMNs and MCNs differentiated by ovarian-type stroma.

METHODS

Medical records for 77 patients with pancreatic cystic neoplasms with mucin secretion were reviewed. Patients were divided into IPMN (n = 70) or MCN (n = 7) according to the presence of ovarian-type stroma, and clinicopathologic parameters were compared between groups.

RESULTS

IPMNs consisted of 32 adenomas, 12 borderline neoplasms, 13 adenocarcinomas in situ, and 13 invasive adenocarcinomas; MCNs included 6 adenomas and 1 invasive adenocarcinoma. The mean age of IPMN patients (66 years) was significantly older than that of MCN patients (55 years). The male:female ratio in IPMN (53/17) was significantly greater (P < .001) than in MCN (0/7). The location of the pancreatic mass differed, with 76% 0f IPMNs occurring in the head, while 86% of MCNs occurred in the body or tail. Mass mean size was significantly smaller (28 mm vs 78 mm, P < .001), and mean diameter of the main pancreatic duct was larger (6.8 mm vs 3.1 mm, P < .001) in IPMN than in MCN. Patulous papilla was present in 44% (31/70) of IPMNs, but none was present in MCNs. Communication between the cyst and main pancreatic duct was more frequent in IPMNs (67/70) than in MCNs (1/7). Overall 5-year survival rates were 84% (IPMN) and 100% (MCN).

CONCLUSIONS

Clinicopathologic differences between IPMN and MCN are much clearer when differentiated by presence of ovarian-type stroma. Favorable prognosis for both neoplasms is offered by complete resection.

Authors+Show Affiliations

Department of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. mura777@hiroshima-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16934608

Citation

Murakami, Yoshiaki, et al. "Intraductal Papillary-mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas Differentiated By Ovarian-type Stroma." Surgery, vol. 140, no. 3, 2006, pp. 448-53.
Murakami Y, Uemura K, Ohge H, et al. Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery. 2006;140(3):448-53.
Murakami, Y., Uemura, K., Ohge, H., Hayashidani, Y., Sudo, T., & Sueda, T. (2006). Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery, 140(3), 448-53.
Murakami Y, et al. Intraductal Papillary-mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas Differentiated By Ovarian-type Stroma. Surgery. 2006;140(3):448-53. PubMed PMID: 16934608.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. AU - Murakami,Yoshiaki, AU - Uemura,Kenichiro, AU - Ohge,Hiroki, AU - Hayashidani,Yasuo, AU - Sudo,Takeshi, AU - Sueda,Taijiro, Y1 - 2006/07/27/ PY - 2005/12/07/received PY - 2006/03/03/revised PY - 2006/03/08/accepted PY - 2006/8/29/pubmed PY - 2006/10/6/medline PY - 2006/8/29/entrez SP - 448 EP - 53 JF - Surgery JO - Surgery VL - 140 IS - 3 N2 - BACKGROUND: Intraductal papillary-mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas have similar clinicopathologic findings. This study was intended to clarify clinicopathologic characteristics in IPMNs and MCNs differentiated by ovarian-type stroma. METHODS: Medical records for 77 patients with pancreatic cystic neoplasms with mucin secretion were reviewed. Patients were divided into IPMN (n = 70) or MCN (n = 7) according to the presence of ovarian-type stroma, and clinicopathologic parameters were compared between groups. RESULTS: IPMNs consisted of 32 adenomas, 12 borderline neoplasms, 13 adenocarcinomas in situ, and 13 invasive adenocarcinomas; MCNs included 6 adenomas and 1 invasive adenocarcinoma. The mean age of IPMN patients (66 years) was significantly older than that of MCN patients (55 years). The male:female ratio in IPMN (53/17) was significantly greater (P < .001) than in MCN (0/7). The location of the pancreatic mass differed, with 76% 0f IPMNs occurring in the head, while 86% of MCNs occurred in the body or tail. Mass mean size was significantly smaller (28 mm vs 78 mm, P < .001), and mean diameter of the main pancreatic duct was larger (6.8 mm vs 3.1 mm, P < .001) in IPMN than in MCN. Patulous papilla was present in 44% (31/70) of IPMNs, but none was present in MCNs. Communication between the cyst and main pancreatic duct was more frequent in IPMNs (67/70) than in MCNs (1/7). Overall 5-year survival rates were 84% (IPMN) and 100% (MCN). CONCLUSIONS: Clinicopathologic differences between IPMN and MCN are much clearer when differentiated by presence of ovarian-type stroma. Favorable prognosis for both neoplasms is offered by complete resection. SN - 0039-6060 UR - https://www.unboundmedicine.com/medline/citation/16934608/Intraductal_papillary_mucinous_neoplasms_and_mucinous_cystic_neoplasms_of_the_pancreas_differentiated_by_ovarian_type_stroma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0039-6060(06)00214-5 DB - PRIME DP - Unbound Medicine ER -